scholarly journals Detailed Multiplex Analysis of SARS-CoV-2 Specific Antibodies in COVID-19 Disease

2021 ◽  
Vol 12 ◽  
Author(s):  
Siggeir F. Brynjolfsson ◽  
Hildur Sigurgrimsdottir ◽  
Elin D. Einarsdottir ◽  
Gudrun A. Bjornsdottir ◽  
Brynja Armannsdottir ◽  
...  
Keyword(s):  
Antibody Response ◽  
Immunological Response ◽  
Receptor Binding Domain ◽  
Igg Antibody ◽  
Nucleocapsid Proteins ◽  
The Third ◽  
Antibody Isotypes ◽  
Iga Antibodies ◽  
Set Up ◽  
Antibody Levels

A detailed understanding of the antibody response against SARS-CoV-2 is of high importance, especially with the emergence of novel vaccines. A multiplex-based assay, analyzing IgG, IgM, and IgA antibodies against the receptor binding domain (RBD), spike 1 (S1), and nucleocapsid proteins of the SARS-CoV-2 virus was set up. The multiplex-based analysis was calibrated against the Elecsys® Anti-SARS-CoV-2 assay on a Roche Cobas® instrument, using positive and negative samples. The calibration of the multiplex based assay yielded a sensitivity of 100% and a specificity of 97.7%. SARS-CoV-2 specific antibody levels were analyzed by multiplex in 251 samples from 221 patients. A significant increase in all antibody types (IgM, IgG, and IgA) against RBD was observed between the first and the third weeks of disease. Additionally, the S1 IgG antibody response increased significantly between weeks 1, 2, and 3 of disease. Class switching appeared to occur earlier for IgA than for IgG. Patients requiring hospital admission and intensive care had higher levels of SARS-CoV-2 specific IgA levels than outpatients. These findings describe the initial antibody response during the first weeks of disease and demonstrate the importance of analyzing different antibody isotypes against multiple antigens and include IgA when examining the immunological response to COVID-19.

scholarly journals Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Andrew D. Moura ◽  
Hernan H. M. da Costa ◽  
Victor A. Correa ◽  
Ana K. de S. Lima ◽  
José A. L. Lindoso ◽  
...  
Keyword(s):  
Protective Immunity ◽  
Vaccine Development ◽  
Immunological Response ◽  
Hospitalized Patients ◽  
Igg Antibody ◽  
Antibody Avidity ◽  
Mild Disease ◽  
Life Threatening ◽  
Antibody Levels

AbstractSARS-CoV-2 is considered a global emergency, resulting in an exacerbated crisis in the health public in the world. Although there are advances in vaccine development, it is still limited for many countries. On the other hand, an immunological response that mediates protective immunity or indicates that predict disease outcome in SARS-CoV-2 infection remains undefined. This work aimed to assess the antibody levels, avidity, and subclasses of IgG to RBD protein, in symptomatic patients with severe and mild forms of COVID-19 in Brazil using an adapted in-house RBD-IgG ELISA. The RBD IgG-ELISA showed 100% of specificity and 94.3% of sensibility on detecting antibodies in the sera of hospitalized patients. Patients who presented severe COVID-19 had higher anti-RBD IgG levels compared to patients with mild disease. Additionally, most patients analyzed displayed low antibody avidity, with 64.4% of the samples of patients who recovered from the disease and 84.6% of those who died in this avidity range. Our data also reveals an increase of IgG1 and IgG3 levels since the 8th day after symptoms onset, while IgG4 levels maintained less detectable during the study period. Surprisingly, patients who died during 8–14 and 15–21 days also showed higher anti-RBD IgG4 levels in comparison with the recovered (P < 0.05), suggesting that some life-threatening patients can elicit IgG4 to RBD antibody response in the first weeks of symptoms onset. Our findings constitute the effort to clarify IgG antibodies' kinetics, avidity, and subclasses against SARS-CoV-2 RBD in symptomatic patients with COVID-19 in Brazil, highlighting the importance of IgG antibody avidity in association with IgG4 detection as tool laboratory in the follow-up of hospitalized patients with more significant potential for life-threatening.

scholarly journals Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2

2021 ◽  
Vol 10 (18) ◽  
pp. 4204
Author(s):  
Marcello Salvaggio ◽  
Federica Fusina ◽  
Filippo Albani ◽  
Maurizio Salvaggio ◽  
Rasula Beschi ◽  
...  
Keyword(s):  
Antibody Response ◽  
Healthcare Workers ◽  
Antibody Concentration ◽  
Clinical Documentation ◽  
Receptor Binding Domain ◽  
Effective Number ◽  
Significant Difference ◽  
Before And After ◽  
Previous Infection ◽  
Antibody Levels

The Pfizer/BioNtech Comirnaty vaccine (BNT162b2 mRNA COVID-19) against SARS-CoV-2 is currently in use in Italy. Antibodies to evaluate SARS-CoV-2 infection prior to administration are not routinely tested; therefore, two doses may be administered to asymptomatic previously exposed subjects. The aim of this study is to assess if any difference in antibody concentration between subjects exposed and not exposed to SARS-CoV-2 prior to BNT162b2 was present after the first dose and after the second dose of vaccine. Data were retrospectively collected from the clinical documentation of 337 healthcare workers who underwent SARS-CoV-2 testing before and after BNT162b2. Total anti RBD (receptor-binding domain) antibodies against SARS-CoV-2′s spike protein were measured before and 21 days after the first dose, and 12 days after the second dose of BNT162b2. Twenty-one days after the first dose, there was a statistically significant difference in antibody concentration between the two groups, which was also maintained twelve days after the second dose. In conclusion, antibody response after receiving BNT162b2 is greater in subjects who have been previously exposed to SARS-CoV-2 than in subjects who have not been previously exposed to the virus, both after 21 days after the first dose and after 12 days from the second dose. Antibody levels, 21 days after the first dose, reached a titer considered positive by the test manufacturer in the majority of subjects who have been previously infected with SARS-CoV-2. Evaluating previous infection prior to vaccination in order to give the least effective number of doses should be considered.

scholarly journals Multiple Antigenic Peptide-Based Vaccines Targeting Ixodes ricinus Neuropeptides Induce a Specific Antibody Response but Do Not Impact Tick Infestation

Pathogens ◽  
2020 ◽  
Vol 9 (11) ◽  
pp. 900
Author(s):  
Consuelo Almazán ◽  
Ladislav Šimo ◽  
Lisa Fourniol ◽  
Sabine Rakotobe ◽  
Jérémie Borneres ◽  
...  
Keyword(s):  
Antibody Response ◽  
Ixodes Ricinus ◽  
Antigenic Peptide ◽  
Tick Feeding ◽  
Igg Antibody ◽  
Individual Level ◽  
Multiple Antigenic Peptide ◽  
New Strategy ◽  
The Individual ◽  
Antibody Levels

Synthetic peptide vaccines were designed to target the neuropeptides innervating Ixodes ricinus salivary glands and hindgut and they were tested for their capacity to afford protective immunity against nymphs or larvae and Anaplasma phagocytophilum-infected nymph infestation, in mice and sheep, respectively. In both models, the assembly of SIFamide (SIFa) or myoinhibitory peptide (MIP) neuropeptides into multiple antigenic peptide constructs (MAPs) elicited a robust IgG antibody response following immunization. Nevertheless, no observable detrimental impact on nymphs was evidenced in mice, and, unfortunately, the number of engorged nymphs on sheep was insufficient for firm conclusions to be drawn, including for bacterial transmission. Regarding larvae, while vaccination of the sheep did not globally diminish tick feeding success or development, analyses of animals at the individual level revealed a negative correlation between anti-SIFa and MIP antibody levels and larva-to-nymph molting success for both antigens. Our results provide a proof of principle and precedent for the use of MAPs for the induction of immunity against tick peptide molecules. Although the present study did not provide the expected level of protection, it inaugurates a new strategy for protection against ticks based on the immunological targeting of key components of their nervous system.

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Infants

1980 ◽  
Vol 89 (3_suppl) ◽  
pp. 351-356 ◽  
Author(s):  
John L. Sloyer ◽  
Laurel J. Karr ◽  
John H. Ploussard ◽  
Gerald D. Schiffman
Keyword(s):  
Antibody Response ◽  
Otitis Media ◽  
Natural Infection ◽  
Young Infant ◽  
Serum Antibody ◽  
Capsular Polysaccharides ◽  
Igg Antibody ◽  
Nasopharyngeal Colonization ◽  
Antibody Levels ◽  
Group 1

The serum antibody response to purified pneumococcal capsular polysaccharides (PCP) was determined in four groups of infants ranging in age from 3 to 24 months. Group 1 consisted of eight infants immunized with an octavalent vaccine containing serotypes 1, 3, 6, 7, 14, 18, 19 and 23 (PCP-8). Group 1 received 25 μg of each serotype at 3–6 months of age and again at 18–24 months. The antibody response after the second immunization was compared to a group of nine patients receiving a primary immunization at 18–24 months and to a group of ten age-matched controls receiving saline placebo. There were no significant differences in mean serum antibody levels between the two groups receiving the PCP-8. A fourth group of 44 infants between 6 and 21 months of age received either PCP-7 or PCP-8 and were followed for two years, at which time simultaneous injections of both vaccines were administered. Types 2, 3, 7, and 8 were most immunogenic but levels six months after immunization were approximately the same as for unimmunized controls with the exception of serotypes 3 and 7 which persisted for about two years. The class of antibody induced either by natural infection or by immunization was preferentially IgG and it was more often induced by the former. There were no significant differences between the serotypes of pneumococci isolated from nasopharyngeal cultures regardless of which vaccine was administered. Finally, the least immunogenic serotypes include 4, 6, 14, 19, and 23 and these are the only serotypes thus far associated with otitis media after immunization. The results suggest that PCP do not induce a lasting immune tolerance at the dose administered in this study; PCP are not very immunogenic in the young infant; PCP antibody tends to rise naturally; IgG antibody is preferentially induced; nasopharyngeal colonization is not altered by PCP immunization; and an association may exist between PCP immunogenicity and subsequent onset of otitis media.

scholarly journals Immunoglobulin G and A Antibody Responses to Bacteroides forsythus and Prevotella intermedia in Sera and Synovial Fluids of Arthritis Patients

2003 ◽  
Vol 10 (6) ◽  
pp. 1043-1050 ◽  
Author(s):  
Ketil Moen ◽  
Johan G. Brun ◽  
Tor Magne Madland ◽  
Turid Tynning ◽  
Roland Jonsson
Keyword(s):  
Immune Responses ◽  
Immunoglobulin G ◽  
Enzyme Linked Immunosorbent Assay ◽  
Prevotella Intermedia ◽  
Igg Antibodies ◽  
Serum Samples ◽  
Igg Antibody ◽  
Iga Antibodies ◽  
Iga Antibody ◽  
Antibody Levels

ABSTRACT The objective of the present study was to investigate immunoglobulin G (IgG) and IgA antibody immune responses to Porphyromonas gingivalis, Prevotella intermedia, Bacteroides forsythus, and Candida albicans in the sera of patients with rheumatoid arthritis (RA), the synovial fluid (SF) of patients with RA (RA-SF samples), and the SF of patients without RA (non-RA-SF samples). An enzyme-linked immunosorbent assay was used to determine IgG and IgA antibody levels in 116 serum samples from patients with RA, 52 RA-SF samples, and 43 non-RA-SF samples; and these were compared with those in SF samples from 9 patients with osteoarthritis (OA-SF samples) and the blood from 100 donors (the control [CTR] group). Higher levels of IgG antibodies against B. forsythus (P < 0.0001) and P. intermedia (P < 0.0001) were found in non-RA-SF samples than in OA-SF samples, and higher levels of IgG antibodies against B. forsythus (P = 0.003) and P. intermedia (P = 0.024) were found in RA-SF samples than in OA-SF samples. Significantly higher levels of IgA antibodies against B. forsythus were demonstrated in both RA-SF and non-RA-SF samples than in OA-SF samples. When corrected for total Ig levels, levels of IgG antibody against B. forsythus were elevated in RA-SF and non-RA-SF samples compared to those in OA-SF samples. Lower levels of Ig antibodies against B. forsythus were found in the sera of patients with RA than in the plasma of the CTR group for both IgG (P = 0.003) and IgA (P < 0.0001). When corrected for total Ig levels, the levels of IgG and IgA antibodies against B. forsythus were still found to be lower in the sera from patients with RA than in the plasma of the CTR group (P < 0.0001). The levels of antibodies against P. gingivalis and C. albicans in the sera and SF of RA and non-RA patients were comparable to those found in the respective controls. The levels of IgG and IgA antibodies against B. forsythus were elevated in SF from patients with RA and non-RA-SF samples compared to those in OA-SF samples. Significantly lower levels of IgG and IgA antibodies against B. forsythus were found in the sera of patients with RA than in the plasma of the CTR group. This indicates the presence of an active antibody response in synovial tissue and illustrates a potential connection between periodontal and joint diseases.

scholarly journals Neutralising reactivity against SARS-CoV-2 B.1.617.2 (Delta) variant by vaccination status and pre-exposure

2021 ◽  
Author(s):  
Enrico Lavezzo ◽  
Monia Pacenti ◽  
Laura Manuto ◽  
Caterina Boldrin ◽  
Margherita Cattai ◽  
...  
Keyword(s):  
Antibody Response ◽  
Post Infection ◽  
Healthcare Workers ◽  
Natural Infection ◽  
Vaccination Status ◽  
Control Groups ◽  
Post Exposure ◽  
The Third ◽  
Antibody Levels

Abstract In February and March 2020, one of the first Italian clusters of SARS-CoV-2 infection was detected in the municipality of Vo’. Positive subjects were followed up at 2 and 9 months post-infection with different immuno-assays and a micro-neutralisation test. Here we report on the results of the third serosurvey conducted in the same population in June 2021, 15 months post-infection, when we tested 61% of the infected individuals (n=76). Antibodies against the spike (S) antigen significantly decreased (P<0.006, Kruskal-Wallis test) among unvaccinated subjects (n=35) and increased (P<0.0001) in vaccinated individuals (n=41), whereas those against the nucleocapsid (N) decreased in the whole cohort. From the comparison with two control groups (naïve Vo’ inhabitants (n=20) and healthcare workers (HCW, n=61)), subjects vaccinated post exposure (hybrid immunity) had higher antibody levels (P<0.0001) than subjects vaccinated when naïve. Two doses of vaccine elicited stronger anti-S antibody response than natural infection (P<0.0001). Finally, the neutralising reactivity of sera against the B.1.617.2 (Delta) was lower than compared to the B.1 strain (median 1:320 versus 1:1280 1/dil, P<0.0001, and 1:640 versus 1:2560 1/dil, P=0.0014, after one or two vaccine doses, respectively), although subjects with hybrid immunity maintained neutralising titres above 1:40 1/dil.

scholarly journals High titers of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding domain and nucleoprotein associate with better neutralization

2020 ◽  
Author(s):  
Maria G. Noval ◽  
Maria E. Kaczmarek ◽  
Akiko Koide ◽  
Bruno A. Rodriguez-Rodriguez ◽  
Ping Louie ◽  
...  
Keyword(s):  
Antibody Response ◽  
Receptor Binding ◽  
Healthcare Workers ◽  
Neutralizing Antibody ◽  
Binding Domain ◽  
Pseudotyped Virus ◽  
Receptor Binding Domain ◽  
Neutralization Capacity ◽  
Antibody Isotypes ◽  
Antibody Titers

AbstractUnderstanding antibody responses to SARS-CoV-2 is indispensable for the development of containment measures to overcome the current COVID-19 pandemic. Here, we determine the ability of sera from 101 recovered healthcare workers to neutralize both authentic SARS-CoV-2 and SARS-CoV-2 pseudotyped virus and address their antibody titers against SARS-CoV-2 nucleoprotein and spike receptor-binding domain. Interestingly, the majority of individuals have low neutralization capacity and only 6% of the healthcare workers showed high neutralizing titers against both authentic SARS-CoV-2 virus and the pseudotyped virus. We found the antibody response to SARS-CoV-2 infection generates antigen-specific isotypes as well as a diverse combination of antibody isotypes, with high titers of IgG, IgM and IgA against both antigens correlating with neutralization capacity. Importantly, we found that neutralization correlated with antibody titers as quantified by ELISA. This suggests that an ELISA assay can be used to determine seroneutralization potential. Altogether, our work provides a snapshot of the SARS-CoV-2 neutralizing antibody response in recovered healthcare workers and provides evidence that possessing multiple antibody isotypes may play an important role in SARS-CoV-2 neutralization.

scholarly journals The Correlation Between IgM and IgG Antibodies With Blood Profile In Patients Infected With COVID 19

2021 ◽  
Author(s):  
Zahra Alibolandi ◽  
Amirreza Ostadian ◽  
Saeed Sayyah ◽  
Hamed Haddad Kashani ◽  
Hassan Ehteram ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Antibody Response ◽  
Laboratory Data ◽  
Severe Illness ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Igg Antibody ◽  
Blood Profile ◽  
Virus Exposure ◽  
Antibody Levels

Abstract Objectives: This study aimed to determine the levels of IgM and IgG antibody response to the severe acute respiratory syndrome coronavirus (SARS-CoV)-2 in coronavirus disease 2019 (COVID-19) patients with different disease severity.Methods: IgM and IgG antibody levels were evaluated via enzyme-linked immunosorbent assay (ELISA). In total, 100 patients with confirmed SARS-CoV-2 infection were enrolled in this study and viral RNA was detected by using Real-time PCR technique. Clinical and laboratory data were collected and analyzed after hospital admission for COVID-19 and two months post-admission. Results: The level of anti-SARS-CoV-2 antibody IgG was significantly higher in the severe patients than those in moderate and mild groups, 2 months after admission. Also, level of IgG was positively associated with increased WBC, NUT and LYM counts in sever than mild or moderate groups after admission to hospital.Conclusion: Our findings suggested that patients with severe illness might experience longer virus exposure times and have a stronger antibody response against viral infection. Thus, they have longer time immunity compared with other groups.

scholarly journals Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis

PLoS ONE ◽  
2020 ◽  
Vol 15 (11) ◽  
pp. e0241164 ◽  
Author(s):  
Victoria Indenbaum ◽  
Ravit Koren ◽  
Shiri Katz-Likvornik ◽  
Mayan Yitzchaki ◽  
Osnat Halpern ◽  
...  
Keyword(s):  
Igg Antibodies ◽  
Serum Samples ◽  
Igg Antibody ◽  
Past Exposure ◽  
Iga Antibodies ◽  
Global Spread ◽  
Diagnostic Capacity ◽  
Antibody Levels ◽  
Antibody Kinetics ◽  
Kinetics Of

The COVID-19 pandemic and the fast global spread of the disease resulted in unprecedented decline in world trade and travel. A critical priority is, therefore, to quickly develop serological diagnostic capacity and identify individuals with past exposure to SARS-CoV-2. In this study serum samples obtained from 309 persons infected by SARS-CoV-2 and 324 of healthy, uninfected individuals as well as serum from 7 COVID-19 patients with 4–7 samples each ranging between 1–92 days post first positive PCR were tested by an “in house” ELISA which detects IgM, IgA and IgG antibodies against the receptor binding domain (RBD) of SARS-CoV-2. Sensitivity of 47%, 80% and 88% and specificity of 100%, 98% and 98% in detection of IgM, IgA and IgG antibodies, respectively, were observed. IgG antibody levels against the RBD were demonstrated to be up regulated between 1–7 days after COVID-19 detection, earlier than both IgM and IgA antibodies. Study of the antibody kinetics of seven COVID 19 patients revealed that while IgG levels are high and maintained for at least 3 months, IgM and IgA levels decline after a 35–50 days following infection. Altogether, these results highlight the usefulness of the RBD based ELISA, which is both easy and cheap to prepare, to identify COVID-19 patients even at the acute phase. Most importantly our results demonstrate that measuring IgG levels alone is both sufficient and necessary to diagnose past exposure to SARS-CoV-2.

THE EFFECT OF AN OESTROGENIC STEROID ON THE PRIMARY ANTIBODY RESPONSE UNDER DIFFERENT HORMONAL ENVIRONMENTS

1972 ◽  
Vol 69 (4) ◽  
pp. 595-601
Author(s):  
Shanta S. Rao ◽  
Yasmin Thanawala ◽  
A. N. Thakur
Keyword(s):  
Antibody Response ◽  
Antibody Production ◽  
Tetanus Toxoid ◽  
Immunological Response ◽  
Primary Antibody ◽  
Ovariectomized Mice ◽  
Primary Antibody Response ◽  
Antibody Levels ◽  
Dose Levels ◽  
Circulating Levels

ABSTRACT The effect of mestranol at 2 dose levels was studied on the antibody response of intact mice as well as on ovariectomized mice, adrenalectomized mice, and adrenalectomized and ovariectomized mice. Tetanus toxoid was used as the immunogen of choice. The results revealed that mestranol produced a dose related enhancement in the circulating levels of antitetanus antibodies in intact animals and to a lesser extent in ovariectomized animals. Adrenalectomy enhanced antibody production only marginally, and the results were not statistically significant. In animals from which both the ovaries and adrenals had been removed, the antibody levels showed a definite increase. Thus mestranol which is less oestrogenic than substituted 17β-oestradiol is capable of enhancing the immunological response in mice.

Sign in / Sign up

Export Citation Format

Share Document